Indivior Pharmaceuticals
INDV
120 hedge funds and large institutions have $1.58B invested in Indivior Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 44 increasing their positions, 24 reducing their positions, and 32 closing their positions.
1,168% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $374K
150% more funds holding in top 10
Funds holding in top 10: 4 → 10 (+6)
83% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 24
82% more capital invested
Capital invested by funds: $867M → $1.58B (+$711M)
16% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 32
12.45% more ownership
Funds ownership: 73.27% → 85.73% (+12%)
3% more funds holding
Funds holding: 116 → 120 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$65.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.3M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$18.2M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13.3M |
| 3 |
Jane Street
New York
|
-$10.6M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$4.43M |
| 5 |
F1I
Fund 1 Investments
Rincon,
Puerto Rico
|
-$4.07M |
INDV Hedge Fund Activity: Q2 2025 in Review
120 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q2 2025, worth a combined $1.58B — up 82% from $867M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new INDV positions and 32 closed out — a net gain of 5 holders — while 44 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $65.4M. The largest seller was Susquehanna International Group, cutting an estimated $20.8M.
- 120 institutional investors held Indivior Pharmaceuticals (INDV) as of Q2 2025, up from 116 in Q1 2025.
- Funds reported $1.58B of Indivior Pharmaceuticals stock for Q2 2025, up 82% quarter-over-quarter.
- 37 funds opened new Indivior Pharmaceuticals positions in Q2 2025 and 32 closed out, a net change of +5 holders.
- The largest Indivior Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $65.4M added.
- The largest Indivior Pharmaceuticals seller in Q2 2025 was Susquehanna International Group, an estimated $20.8M sold.
Based on aggregated 13F filings for Q2 2025.